New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...
Sorbitol-supplemented diet combined with neoadjuvant chemoimmunotherapy in locally advanced gastric cancer: Preliminary results from a randomized controlled trial. Primary analysis results of a phase ...
Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...
Lung cancer remains the leading cause of cancer-related mortality worldwide. Although small cell lung cancer (SCLC) accounts for a smaller percentage of lung cancer cases, it has remained a ...
T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...
A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment. Targeting ...
The two main categories for lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Large cell lung cancer (LCLC) is a type of NSCLC. While the conditions share some ...
A newly identified vulnerability of small cell neuroendocrine carcinoma could represent a potential treatment strategy for these aggressive and difficult-to-treat cancers. University of California, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results